Yasuaki Muramatsu

Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis

Masato Takahashi, Hiroyuki Yasojima, Tomofumi Osako, Kenichi Inoue et autres

jp, ch (code pays fourni par la source)

Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)

Hiroko Bando, Aya Ueda, Kaori Terata, Mihoko Doi et autres

jp, us (code pays fourni par la source)

Abstract P4-10-03: Potential risk factors for health-related quality of life (HRQoL) in palbociclib (PAL) plus endocrine therapy (ET) and ET alone patients with HR+/HER2- advanced breast cancer (ABC): exploratory analysis from 6-month longitudinal study (JBCRG-26)

Shigehira Saji, Mari S. Oba, Aya Ueda, Kaori Terata et autres

Abstract P4-07-22: Real world effectiveness of overall survival (OS) with palbociclib (PAL) plus (+) endocrine therapy (ET) in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) patients in Japan

Michiko Tsuneizumi, Tetsuhiro Yoshinami, Shigenori E. Nagai, Masaya Hattori et autres

Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2– advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

Shigenori E. Nagai, Masaya Hattori, Tetsuhiro Yoshinami, Hiroko Masuda et autres

jp (code pays fourni par la source)

Association between physical activity and quality of life in Japanese adults aged 85 to 89 years: a cross-sectional study

Yasuaki Muramatsu, Yuko Oguma, Yukiko Abe, Azusa Hara et autres

jp (code pays fourni par la source)

Epidemiology of adverse events related to sports among community people: a scoping review

Akihiro Hirata, Yoshinobu Saito, M Nakamura, Yasuaki Muramatsu et autres

jp (code pays fourni par la source)

Abstract PO1-05-05: Overall survival (OS) and subsequent therapy patterns in Japanese patients with HR+/HER2− advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET) in first-line setting (1L)

Masato Takahashi, Tomofumi Osako, Hiroyuki Yasojima, Kenichi Inoue et autres

jp, us (code pays fourni par la source)

Abstract PO1-05-06: Health-related QOL and physical activity collected via wearable device in patients with HR+/HER2− advanced breast cancer in Japan treated with palbociclib+endocrine therapy (ET) or ET alone: 6-month longitudinal study (JBCRG-26)

Hiroko Bando, Mari S. Oba, Aya Ueda, Kaori Terata et autres

jp (code pays fourni par la source)

Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole

Masato Takahashi, Tomofumi Osako, Hiroyuki Yasojima, Kenichi Inoue et autres

jp (code pays fourni par la source)

Association between physical activity patterns and quality of life in Japanese adults aged 85 to 89 years: a cross-sectional study

Yasuaki Muramatsu, Yuko Oguma, Yukiko Abe, Azusa Hara et autres

jp (code pays fourni par la source)

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan

Masataka Sawaki, Yasuaki Muramatsu, Kanae Togo, Hiroji Iwata

jp (code pays fourni par la source)